NEW YORK, Sept. 7, 2016 /PRNewswire/ -- Notice is hereby
given that Faruqi & Faruqi, LLP has filed a class action
lawsuit in the United States District Court for the Southern
District of California, case no.
3:16-cv-02084, on behalf of shareholders of Sequenom, Inc.
("Sequenom" or the "Company") (NasdaqGS:SQNM) who held
Sequenom securities and have been harmed by Sequenom's and its
board of directors' (the "Board") alleged violations of Sections
14(d)(4), 14(e), and 20(a) of the Securities Exchange Act of 1934
(the "Exchange Act") and of the United States Securities and
Exchange Commission ("SEC") Rule 14d-9 in connection with the sale
of the Company to Laboratory Corporation of America Holdings
("LabCorp").
On July 26, 2016, the Company
LabCorp and its wholly-owned subsidiary, Savoy Acquisition Corp.
("Merger Sub") entered into an Agreement and Plan of Merger
("Merger Agreement") under which LabCorp, through Merger Sub,
commenced a tender offer on August 9,
2016 ( "Proposed Transaction"). Following the completion of
the tender offer, and subject to the terms and conditions of the
Merger Agreement, Merger Sub will be merged with and into Sequenom,
with Sequenom surviving as a wholly owned subsidiary of
LabCorp.
If you wish to obtain information concerning this action or
view a copy of the complaint, you can do so by clicking here:
www.faruqilaw.com/SQNMnotice.
Pursuant to the terms of the Merger Agreement, which was
unanimously approved by the Board, Sequenom shareholders will
receive $2.40 in cash per share for
each share of Sequenom they own. The complaint claims that this
offer is inadequate in light of the Company's recent financial
performance and strong growth prospects and alleges that the
Schedule 14D-9 Solicitation/Recommendation Statement (the "14D-9")
provides materially incomplete and misleading information about the
Company's financials, and the procedural fairness of the Proposed
Transaction, in violation of Sections 14(d)(4), 14(e), and 20(a) of
the Exchange Act.
Take Action
Plaintiff is represented by Faruqi & Faruqi, LLP, a law firm
with extensive experience in prosecuting class actions, and
significant expertise in actions involving corporate fraud.
Faruqi & Faruqi, LLP, was founded in 1995 and the firm
maintains its principal office in New
York City, with offices in Delaware, California, and Pennsylvania.
If you wish to serve as lead plaintiff, you must move the Court
no later than 60 days from today. Any member of the putative
class may move the Court to serve as lead plaintiff through counsel
of their choice, or may choose to do nothing and remain an absent
class member. If you wish to discuss this action, or have any
questions concerning this notice or your rights or interests,
please contact:
Nadeem Faruqi, Esq.
James M. Wilson, Jr., Esq.
FARUQI & FARUQI, LLP
685 3rd Avenue, 26th Floor
New York, NY 10017
Tel.: (212) 983-9330
Fax: (212) 983-9331
E-mail: nfaruqi@faruqilaw.com
jwilson@faruqilaw.com
Logo - http://photos.prnewswire.com/prnh/20120119/MM38856LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/faruqi--faruqi-llp-announces-filing-of-a-class-action-lawsuit-against-sequenom-inc-300324069.html
SOURCE Faruqi & Faruqi, LLP